The prognostic value of neuron specific enolase in head injury  by El-Maraghi, Sameh et al.
The Egyptian Journal of Critical Care Medicine (2013) 1, 25–32The Egyptian College of Critical Care Physicians
The Egyptian Journal of Critical Care Medicine
http://ees.elsevier.com/ejccm
www.sciencedirect.comORIGINAL ARTICLEThe prognostic value of neuron speciﬁc enolase
in head injurySameh El-Maraghi b,*, Heba Yehia a, Hazem Hossam a, Ahmed Yehia a,
Hossam Mowafy aa Critical Care Department, Faculty of Medicine, Cairo University, Egypt
b Critical Care Department, Faculty of Medicine, Beni Suef University, EgyptReceived 21 October 2012; revised 2 December 2012; accepted 4 December 2012











er review under responsibili
are Physicians.
Production an
90-7303  2012 The Egyptia





httpense.Abstract Background: The development and the use of biochemical markers for assessment of
brain injury severity have been of considerable interest. The most promising marker of brain dam-
age is considered to be neuron-speciﬁc enolase (NSE); predominantly located in neurons and neu-
roectodermal cells.
Purpose: To investigate the serum levels of NSE in patients with head injury admitted to ICU
and to correlate them with their outcome and other clinical parameters.
Methods: A total of 20 patients admitted to the critical care unit, MISR University for science
and technology Hospital with head injury; including traumatic brain injury and those with stroke
either ischemic or hemorrhagic stroke were included in the study. NSE was measured in venous
blood samples collected on ICU admission and at 48 h of admission. Clinical data and ﬁnal out-
come of survival/mortality rates were recorded for all patients.
Results: Patients age ranged from 20 to 80 years with a mean (50.8 ± 16.5), 18 of them were
males (90%) and two were females (10%). There were no statistical signiﬁcant difference between
NSE level in traumatic (8.8 ± 8.1) or non traumatic patients (10.9 ± 7.9) (p value = 0.3). There
was a signiﬁcant correlation between NSE level and the progression of CT ﬁndings. Moreover,
NSE showed statistically signiﬁcant higher level estimation in those patients with moderate and
severe brain injury (17.2 ± 13.5) than in mild brain injury (7.1 ± 4.8) (p= 0.04) together with sig-
niﬁcant negative correlation between NSE and GCS on admission (p= 0.01 & r= 0.564) as well1001678089/33365407.
o.com (S. El-Maraghi).
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26 S. El-Maraghi et al.as the changes in GCS assessment after 48 h. Upon estimating the prognostic role of NSE and its
ability in detecting outcome; NSE was signiﬁcantly higher in non survivors (20 ± 14) than in sur-
vivors (8.9 ± 6.7) (p< 0.05). Also, it was signiﬁcantly higher in those with bad outcome (severe
disability) than those who recover or with mild disability (p< 0.05). By statistical analysis; an opti-
mal cutoff value of NSE level of 18 lg/L was determined to predict ICU mortality and 7.9 lg/L to
predict bad outcome with a high sensitivity and speciﬁcity.
Conclusion: Neuron speciﬁc enclose can be used as a potentially useful marker for brain damage
and can be considered to be a relevant parameter for assessing the prognosis of brain injury.
 2012 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V.
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Brain injury resulting from traumatic, ischemic and/or haem-
orrhagic etiology is a signiﬁcant international health concern,
representing a potentially catastrophic debilitating medical
emergency with poor prognosis for long-term disability [1].
Ranking of head injuries by severity is an essential part of
clinical management, prognosis, treatment trials, and legal
assessment. Various methods for assessing severity are re-
viewed. Clinical assessment of brain function and neuro-imag-
ing techniques constitute the common ways for diagnosis and
assessment of brain damage. Despite the substantial progress
in clinical and neuro-monitoring it remains difﬁcult to quantify
the extent of primary brain injury as well as the ongoing sec-
ondary damage and hence they cannot guide efﬁcient thera-
peutic measures and prognosticate effectively the ﬁnal
outcome [2,3].
Therefore, the development and the use of biochemical
markers for assessment of brain injury severity have been of
considerable interest. Biomarkers would have important appli-
cations in diagnosis, prognosis and clinical research of brain
injuries. Biochemical markers are considered to be a simple
and a rapid diagnostic tool that will immensely facilitate allo-
cation of the major medical resources required to treat brain
injuries [4].
The bulk of research in brain injury has focused on neuron-
speciﬁc enolase (NSE) and S-100b. Currently, the most prom-
ising marker of brain damage in the literature is considered to
be NSE [5].
Neuron Speciﬁc Enolase (NSE) is a glycolytic enzyme fam-
ily (enolases) predominantly located in neurons and neuroecto-
dermal cells and serves as a marker of neuronal damage.
Increased concentration of NSE can be measured in the cere-
brospinal ﬂuid (CSF) and in peripheral blood after neuronal
damage and provides a reliable laboratory indicator of the de-
gree of brain cell damage, and may allow for early prediction
of outcome [6,7].
Aim of the work
Investigate the serum levels of NSE in patients with head in-
jury admitted to ICU and to correlate them with their outcome
and other clinical parameters and to assess the validity of out-
come prediction with this serum marker in patients with head
injury.Patients and methods
Patients
The study protocol was approved by the local Ethics. We pro-
spectively enrolled twenty patients with head injury, admitted
to Critical care unit of the ‘‘MISR university for science and
technology hospital’’; from January 2010 to December 2010.
Informed consent was given by the patient or immediate rela-
tive (ﬁrst degree). This study did not interfere with the current
medical practice of the investigator. No invasive medical pro-
cedure is required by the protocol. The investigator can decide
for any treatment that is for the best interest of his patients.
Inclusion criteria
(1) AgeP 18 years.
(2) Patients with head injury, including traumatic brain
injury.
(3) Patients with stroke either ischaemic or hemorrhagic
stroke.
Patients were selected randomly and prospectively and in-
cluded into the study on the day of ICU admission and they
were followed up till the day of discharge or demise.
Evaluation of patients
All included patients were subjected to the following:
(1) Full clinical evaluation: Including history, obtained usu-
ally from family members, police ofﬁcers, paramedics or
witnesses, and appropriate physical and neurological
examination with special emphasis on vital signs and
GCS; which were evaluated at the day of admission
and 48 h later.The patients were classiﬁed according to
GCS as: mild head injury (GCS 13–15), moderate head
injury (GCS 9–12), and severe head injury (GCS 6 8).
(2) Laboratory investigations:n Routine labs: CBC (complete blood count): Hemoglo-
bin, Hematocrit, White blood cells and platelet
count, Coagulation proﬁle: PT (prothrombin time),
PC (prothrombin concentration), INR and PTT
(partial thromboplastin time), ABGs (arterial blood
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transferase), AST (Aspartate aminotransferase), BI-
L (bilirubin) and albumin, Kidney function tests:
Na, K, Creatinine and Urea, and random blood sug-
er.These routine labs were withdrawn on study day
1 and then 48 h later.
n Labs speciﬁc for our study: Venous blood samples for
NSE were drawn during the ﬁrst 24 h of admission
and after 48 h of their admission. Blood samples were
allowed to clot and then centrifuged to separate the
serum according to common procedures. The serum
was separated from the clot within 60 min of collec-
tion to avoid leaking of NSE from blood cells. Pla-
sma was not used as it is not recommended since
signiﬁcant amounts of NSE can be released from
platelets. Haemolysed samples had not been used
since erythrocytes contain signiﬁcant amounts of
NSE. Samples preserved at 70 C and stored for
analysis. Frozen samples allowed thawing slowly at
2–8 C over night and then the samples brought to
room temperature before analysis.
n The serum concentration of NSE was measured by
using solid-phase enzyme immunoassay. The essay
used a highly speciﬁc monoclonal antibody to NSE.
During the incubation, the serum NSE reacted with
the antibody, which was immobilized on polystyrene
beads, and then with a rabbit polyclonal antibody to
form a ‘sandwich’. The beads were washed to remove
any unbound rabbit antibody and incubated with a
highly puriﬁed goat antibody against rabbit immuno-
globulin, which was conjugated to horseradish perox-
idase. The beads were rewashed to remove any
unbound antibody enzyme conjugate and incubated
with an enzyme substrate solution. The change in
substrate color was measured with a Cobas photom-
eter and was directly proportional to the amount of
the NSE present [8].(3) Imaging studies: Including chest X-ray, echocardiogra-
phy and CT brain; was performed in all patients on
admission and was initially interpreted by a radiologist
consultant. CT scans were repeated at several follow
up examinations depending on clinical course.
(4) Clinical data: Length of ICU stay, ﬁnal outcome of sur-
vival/mortality rates were reported for all patients until
ICU discharge.
Statistics
Data were statistically described in terms of range, mean ±
standard deviation (±SD), median, frequencies (number of
cases) and relative frequencies (percentages) when appropriate.
Comparison of quantitative variables between the study
groups was done using simple t-test (for two variables) or AN-
OVA test (for more than two variables). For comparing cate-
gorical data, Chi square (v2) test was performed. Exact test was
used instead when the expected frequency is <5. Receiver
operator characteristic (ROC) analysis was used to determine
the optimum cut off value for the studied diagnostic markers.
Pearson correlation coefﬁcient was used for analysis of relation
of bivaried. Linear regression was used to estimate the coefﬁ-
cient of linear equation involving one or more independentvariable that best predict the value of dependant variable. A
probability value (p value) less than 0.05 was considered statis-
tically signiﬁcant. All statistical calculations were done using
computer programs Microsoft Excel 2003 (Microsoft Corpora-
tion, NY, USA) and SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.Results
(I) Demographic and baseline clinical data at ICU admis-
sion (Table 1).Patients demographic and clinical data
are shown in Table 1.
(II) NSE measurement: The mean NSE level on admission
was 9.9 ± 7.8 and after 48 h of admission the mean
was (12.1 ± 11.1).
(III) Correlative analysis:
(a) Correlation between NSE and age and gender: T-
here was no signiﬁcant correlation between NSE
with age of patients, (p= 0.15, r= 0.5 on admis-
sion and p= 0.33 and r= 0.1 48 h after admis-
sion). On the other hand, NSE was signiﬁcantly
higher in males (10.4 ± 8.1) than in females
(5.5 ± 0.7) (p= 0.02).
(b) Correlation between NSE with traumatic and non
traumatic patients: There was no signiﬁcant differ-
ence of NSE level in traumatic (mean NSE on
admission was 8.8 ± 8.1 and NSE after 48 h was
9.4 ± 11.6) or non traumatic patients (mean
NSE on admission was 10.9 ± 7.9 and NSE after
48 h was 14.4 ± 10.8) (p value >0.05).
(c) Correlation between NSE level and severity of brain
injury: NSE on admission was higher in the group
with moderate to severe brain injury (mea-
n = 13.1 ± 10.2) than in mild head injury (mea-
n = 6.8 ± 2) but it was not signiﬁcant
(p= 0.07). NSE after 48 h of admission was sig-
niﬁcantly higher in the group with moderate to
severe brain injury (mean = 17.2 ± 13.5) than in
mild brain injury (mean = 7.1 ± 4.8) (p= 0.04).
(d) Correlation between NSE level and GCS: There
was a signiﬁcant negative correlation between
NSE and GCS on admission (p= 0.01 & r=
0.564), also NSE on admission is negatively
correlated with GCS 48 h after admission
(p= 0.008 & r= 0.57). NSE 48 h after admis-
sion had signiﬁcant negative correlation with
GCS 48 h after admission (p= 0.001 &
r= 0.675) (Fig. 1)
(e) Correlation between NSE level and the change in
GCS: There was a signiﬁcant increase in NSE
48 h after admission in patients with documented
deterioration of GCS (mean NSE 48 h after
admission in those who improved, the same and
deteriorating GCS was 9.8, 10.9 and 30, respec-
tively with p-value was 0.04) while NSE on admis-
sion showed no statistically signiﬁcant difference
between these groups (mean NSE on admission
was 8.7, 9.1 and 20, respectively with
p-value = 0.16). (Table 2)
Table 1 Demographic and clinical data of patients entered
into the study.
Characteristics Value
Age, mean ± SD in years (range) 50.8 ± 16.5 (20–80)
Male: female sex (ratio) 18: 2 (9)





Ischemic heart disease 3 (15%)
Neurological manifestation 12 (60%)
Primary head injury (No. of patients (%))
Traumatic brain injury 9 (45%)
Ischemic stroke 5 (25%)
Hemorrhagic stroke 6 (30%)
GCS on admission (No. of patients (%))
Mild (13–15) 10 (50%)
Moderate (9–13) 8 (40%)
Severe (68) 2 (10%)
Severity according to change in GCS 48 h
after admission (No. of patients (%)
Improve 12 (60%)
The same 6 (30%)
Worsening 2 (10%)
Change in the CT ﬁnding
(No. of patients (%))
Improve 8 (40%)
The same 10 (50%)
Deteriorate 2 (10%)
Outcome of the enrolled patients
(No. of patients (%))
Survivors 18 (90%)
Recovery 6 (30%)
Moderate disability 7 (35%)
Severe disability 5 (25%)
Non survivors 2 (10%)
N: number; GCS: Glasgow Coma Scale; CT: computed
tomography.
Figure 1 Correlation between NSE and GCS.
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the CT: Although NSE on admission was higher
in patients who were deteriorated according to
CT ﬁndings (mean; 7.9, 9.6 and 20 in patients
who improved, the same and with worse CT
ﬁndings respectively), it was not signiﬁcant
(p= 0.15). NSE 48 h after admission was signiﬁ-
cantly higher with the worsening of CT ﬁnding
(mean; 9, 11 and 30, respectively with p= 0.04)
(Table 3).
(g) Correlation between NSE level and outcome: NSE
on admission was signiﬁcantly higher in non sur-
vivors (mean = 20 ± 14.1) than in survivors
(mean = 8.8 ± 6.6) with p= 0.05. Also NSE 48 h
after admission was more signiﬁcantly higher in
non survivors (mean = 30 ± 14.1) than in survi-
vors (mean = 10.2 ± 9.3) with p= 0.01. Regard-
ing the survivors, NSE on admission showed no
signiﬁcant difference among survivors (p= 0.25)
but NSE 48 h after admission showed signiﬁcantdifference among survivors; mean NSE 48 h after
admission was 5.9, 13.2 and 11.1 in recovered pts,
who had moderate disability & those with severe
disability respectively with p= 0.05 (Table 4).(IV) Prognostic ability of NSE: Receiver operator character-
istic (ROC) curve was calculated for the use of NSE level
as a predictor for mortality. The area under curve
(AUC) for NSE to predict ICU mortality was 0.93
(95% conﬁdence interval, 0.809–1.052). The optimal
cutoff value of NSE level to predict ICU mortality was
18 lg/L with a sensitivity of 100% and speciﬁcity of
90% (Fig. 2a).
Also a cutoff value of NSE level to predict bad outcome
was 7.9 lg/L with a sensitivity 85% and speciﬁcity 77%. The
area under curve for NSE to predict bad outcome was 0.76
(95% conﬁdence interval, 0.53–0.99) (Fig. 2b).
Discussion
Assessment of severity of brain damage is an essential part of
clinical management, prognosis and treatment trials. Clinical
examination, neuro-monitoring methods and the modern neu-
ro-imaging techniques are quite often not sufﬁcient to evaluate
and quantify the severity of the brain injury and hence they
cannot guide efﬁcient therapeutic measures and prognosticate
effectively the ﬁnal outcome. The problem becomes even more
prominent with comatosed patients with facial trauma and/or
pre-existing pupillary abnormalities [9].
The measurement of NSE concentrations in serum and
cerebrospinal ﬂuid (CSF) following cerebral ischemia and
traumatic head injury provides a reliable laboratory indicator
of the degree of brain cell damage, and may allow for early
prediction of outcome. NSE is useful for both diagnostic and
prognostic purposes. It can predict infarct volume, hemor-
rhagic transformation and other clinical variables [10].
Therefore, we tried in this study to investigate the prognos-
tic value the serum level of neuron speciﬁc enolase (NSE) in
patients with head injury, with particular regard to its role in
predicting illness severity, clinical course and mortality.
Table 2 Correlation between NSE and the change in GCS.
GCS change N Mean SD p Value
NSE on admission Improved 12 8.7 7.04 0.16
The same 6 9.1 6.4
Deteriorating 2 20 14.1
NSE 48 h after admission Improved 12 9.8 10.3 0.04
The same 6 10.9 7.6
Deteriorating 2 30 14.1
Table 3 Correlation between NSE and the change in CT.
CT N Mean SD p Value
NSE on admission Improve 8 7.9 2.2 0.15
The same 10 9.6 8.8
Worse 2 20 14.1
NSE48 h after admission Improve 8 9.1 7.7 0.046
The same 10 11.08 10.7
Worse 2 30 14.1
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80 years with mean age (50.8 ± 16.5). We compared NSE in
different ages and found that there is no signiﬁcant correlation
between NSE and age (p= 0.15 and r= 0.5).
This is in agreement with Casmiro et al. [11] who studied
108 patients (68 men and 40 females) without neurological dis-
eases to analyze the NSE relationship with sex and age. This
study showed that NSE level not signiﬁcantly increasing with
advancing age (p= 0.16, r= 0.027).
Also it goes with Vos et al. [12] who conducted a study on
85 patients with severe brain injury (admission GCS 6 8)
found that NSE not signiﬁcantly correlated with age. Also
Nygaard et al. [13] found that serum NSE not correlated with
age and only CSF-NSE correlated signiﬁcantly with age.
Our study included 18 males (90%) and 2 females (10%);
when we compared NSE level in both sexes we found that
NSE on admission was signiﬁcantly higher in males
(10.8 ± 8.1) than in females (5.5 ± 0.7) (p= 0.02) in spite of
there is no signiﬁcant difference in NSE 48 h after admission
between males and females.
This is in agreement with de Kruijk et al. [14] who studied
serum NSE of 91 controls 14% of them was female and 86%
were male. The median NSE concentration in serum of male
controls was higher than in serum of female controls (9.7 ver-
sus 7.6 mg/L; p= 0.037).
Also it goes with Nygaard et al. [13] who collected serum
and CSF-NSE from 63 males and 24 females. They found that
NSE concentration was signiﬁcantly higher in males than in fe-
males. However, both Casmiro et al. [11] and Vos et al. [12]
found that NSE not signiﬁcantly correlating to gender.
In our study, patients were grouped according to the cause
of admission and CT ﬁndings into traumatic brain injury (TBI)
which accounted for 45% (n= 9) and non traumatic which in-
clude those with ischaemic stroke (IS) which accounted for
25% (n= 5) and hemorrhagic stroke (ICH) which accounted
for 30% (n= 6). We compared NSE in these groups and
found that there was no signiﬁcant difference between NSE le-
vel in traumatic (8.8 ± 8.1) or non traumatic patients
(10.9 ± 7.9) (p value = 0.5).As NSE was not affected by different etiology, we com-
pared the enrolled patients despite the variation in the cause
of brain injury. We found no study comparing NSE level in
traumatic and non traumatic brain injury; some studies inves-
tigate serum NSE in those with traumatic brain injury and oth-
ers investigate NSE in those with ischemic and hemorrhagic
stroke. Our study may be the only one to do this comparison.
Regarding to the degree of severity of head injury, we dem-
onstrated that NSE on admission was insigniﬁcantly higher in
the group of moderate to severe brain injury (13.1 ± 10.2)
than in mild brain injury (6.8 ± 2) with a p-value of 0.07.
On the other hand; NSE 48 h after admission was signiﬁcantly
higher in the group of moderate to severe brain injury
(17.2 ± 13.5) than in mild brain injury (7.1 ± 4.8) with a p-va-
lue of 0.04. Moreover, we found that there was a signiﬁcant
negative correlation between NSE on admission and on admis-
sion GCS (p= 0.01 & r= 0.564) and NSE 48 h after admis-
sion is more signiﬁcantly correlated with GCS 48 h after
admission (p= 0.001 & r= 0.675).
This is in agreement with Zahra et al. [15] who studied 45 pa-
tients; 14 of them with moderate to severe head injury
(GCS < 12) and the rest of them with minor head injuries
(GCS score >12) and the results showed serum levels of NSE
in those with moderate to severe head injury (22.8 ± 13.3)
was signiﬁcantly higher than in mild (9.8 ± 7.7) with
p< 0.01. But he found no signiﬁcant statistical correlation be-
tween NSE concentration and GCS (p= 0.23).
Also it goes with Guezel et al. [16], Rothoeral et al. [28] and
Herrmann et al. [18] who found that the levels of neuron-spe-
ciﬁc enolase were signiﬁcantly higher in the patients with se-
vere brain injury (GCS 6 8) and there was a signiﬁcant
negative correlation between the serum NSE levels and GCS.
This is in contrast with Vos et al. [12] who conducted the
study only on patients with severe brain injury and did not
found that signiﬁcant correlation between NSE and GCS.
In our study we assessed improvement of patients by com-
paring their GCS on admission and after 48 h. We found that
12 patients (60%) improved, 6 patients (30%) were with the
same GCS and 2 patients (10%) were deteriorating. When
Table 4 Correlation between NSE and the outcome.
Outcome N Mean SD p Value
NSE on admission Non survivors 2 20 14.1 0.25
Survivors 18 8.8 6.6
Recovery 6 7.1 1.9 0.05
Mod. disability 7 9.2 9.2
Severe disability 5 10.5 6.9
NSE 48 h after admission Non survivors 2 30 14.1 0.05
Survivors 18 10.2 9.3
Recovery 6 5.9 2.07 0.01
Mod. disability 7 13.2 13.9
Severe disability 5 11.1 5.1
Note: Moderate & severe disability is according to the degree of dependence.
ROC Curve












Figure 2a Prognostic value of NSE to predict mortality.
ROC Curve












Figure 2b Prognostic value of NSE that predict bad outcome.
30 S. El-Maraghi et al.comparing change of NSE level in these groups we found that
NSE level was 9.8, 10.9 and 30 in the 3 groups, respectively
and NSE level was signiﬁcantly higher in those with deteriorat-
ing GCS (p= 0.04).
This is in agreement with Meric et al. [19] who found that
NSE levels rose as GCS fell. Also Herrmann et al. [18] stated
that patients with moderate to severe brain injury (GCS 6 12)
exhibited signiﬁcantly higher NSE concentrations and a signif-
icantly longer release compared to patients with minor head in-
jury (GCS = 13–15). This explains why in our study NSE 48 hafter admission was more signiﬁcant in detecting severity of
head injury.
In our study, follow up CT brain was repeated after 48 h of
admission. It was observed that the patients fell into three
broad categories. The ﬁrst was the resolving category. In these
patients, the contusions and/or infarctions were resolving. This
category accounted for 40% (n= 8) of patients. The second
was the static category which accounted for 50% (n= 10).
In these patients, the CT ﬁndings were with the same ﬁnding
as admission CT. The third category (n= 2) accounted for
10% was the progressive category. In these patients there
was extension of the initial infarction/hemorrhage or hemor-
rhagic transformation of the infarction. NSE levels were com-
pared in all of the three categories and revealed that NSE value
get higher with deterioration of head injury. NSE 48 h after
admission was more signiﬁcant than NSE on admission in
detecting the progression of brain injury. p Value for NSE
48 h after admission was 0.04 versus 0.15 or NSE on
admission.
This is in agreement with Manfred et al. [20] who found a
high signiﬁcant correlation between NSE and lesion in CT
and this correlation reached maximum value at second day
of brain insult (r= 0.83, p< 0.0001). He also found that ser-
um NSE did not differ with the type of lesion whether hemor-
rhagic or ischemic stroke but to the lesion size.
Also it agrees with Zahra et al. [15], Vos et al. [12] and Nae-
imi et al. [21] who observed a statistically signiﬁcant correla-
tion between increased levels of NSE and CT changes
(p< 0.04).
Again in agreement with our study, Samit [22], found a
strong correlation between serum levels of NSE with the pro-
gression of head injury (p< 0.001). In the resolving group, the
marker levels showed a decreasing trend.
In our study survivors accounted for 90% (n= 18 pa-
tients), and including those with good recovery 6 patients
(30%), 7 patients (35%) with moderate disability and 5 pa-
tients (25%) with severe disability. While the non survivors ac-
counted for 10% (n= 2). When we compared NSE in these
groups, we found that NSE on admission was signiﬁcantly
higher in non survivors (20 ± 14) than in survivors
(8.9 ± 6.7) (p-value 0.05). NSE 48 h after admission was more
signiﬁcantly higher in non survivors (mean = 30 ± 14) than in
survivors (mean = 10.2 ± 9.3) (p= 0.01). Also we found that
NSE 48 h after admission was signiﬁcantly higher with bad
outcome (mean = 5.9, 13.2 and 11.1 in patients with good
The prognostic value of neuron speciﬁc enolase in head injury 31recovery, moderate and severe disability respectively with a p
value of 0.05).
This is in agreement with Samit [22], who found that NSE
in those with good outcome (17 ± 5.1) and in those with poor
outcome (25.4 ± 5.1). A strong statistical signiﬁcance exists
between serum NSE level and outcome assessment (p value
<0.001).
Also David et al. [23], Bandyopadhyay et al. [17] and Vos
et al. [12] found that NSE level correlate with outcome. Pa-
tients with bad outcome (death or severe disability) had a high-
er concentration of NSE than in patients with good outcomes
(survivors or with minimal disability) (r= 0.319, p< 0.0001)
and the enzyme levels after 48 h were more signiﬁcant than
their level on admission in detecting outcome. p Value for
NSE2 was <0.001 versus 0.065 for NSE1.
This also agrees with Olivecrona et al. [24], Guzel et al. [16],
Sawauchi et al. [25], and Sogut et al. [26] who found that NSE
was signiﬁcantly higher in patients who died compared to the
survivors. Increased concentration of NSE even precede
changes in clinical or other diagnostic parameter.
This is in contrast with Raabe et al. [27] who studied 82
patients with head injury, 49 showed a favorable outcome
(60%) and 33 showed unfavorable outcome (40%) after
6 months with a mortality rate of 38% (31 patients). There
was no signiﬁcant difference between the maximum levels
of NSE of both outcome groups (NSE was 26.7 lg/L in
favorable outcome versus 12 lg/L in unfavorable outcome
with a p value of 0.09).
In our study a receiver operating characteristic (ROC)
curve was calculated for the use of NSE level as a predictor
of mortality and bad outcome. The area under the ROC
curve for NSE to predict mortality was 0.93. The optimal
cutoff value for NSE levels to predict mortality was
18 lg/L. This cutoff value gave a sensitivity of 100% and
speciﬁcity of 90%. The area under the ROC curve for
NSE to predict bad outcome was 0.76. The optimal cutoff
value for NSE levels to predict bad outcome was 7.9 lg/L.
This cutoff value gave a sensitivity of 85% and speciﬁcity
of 77%.
Vos et al. [12] found that levels >21.7 lg/L strongly could
predict death and that of 3.95 lg/L strongly predict bad out-
come. Meric et al. [19] found that cut-off level of NSE at
20 ng/mL could detect poor neurological outcome by a sensi-
tivity 87% and speciﬁcity 82.1%. The area under curve was
0.93. Bandyopadhyay et al. [17] found that NSE at level
21 ng/dL could detect bad outcome with a sensitivity 86%
and speciﬁcity 47%. The area under curve was 0.83. Samit
[22], calculated cutoff values for poor outcome and found that
NSE > 28.2 lg/L can detect poor outcome with speciﬁcity
96.6% and sensitivity 80%. ROC analysis revealed that area
under curve was 0.86.
The difference obtained in cut-off point could be explained
by that Serum and CSF-NSE values vary widely among differ-
ent studies on normal populations because of different deter-
mination methods; therefore, each laboratory should obtain
its own reference values.Conclusion
Neuron speciﬁc enclose can be used as a potentially useful
marker for brain damage and can be used as a simple, rapidand easy to perform and interpret test for early prognosis
and prediction of adverse outcome.Recommendation
(1) Application of NSE as a routine scoring tool on admis-
sion and follow up for all patients admitted with head
injury.
(2) Serial measurement of NSE as it will help to monitor the
efﬁcacy of therapeutic interventions delivered.
(3) Future large scale studies comparing the release pattern
of NSE between patients admitted with traumatic brain
injury and those with non traumatic brain injury.References
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